The Emperor's New Clothes. Another Cypher Versus Taxus Post-Hoc Meta-Analysis**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 14, 2007, Pages 1381-1385

  Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PACLITAXEL; PYRIDINE DERIVATIVE; RAPAMYCIN; THIENOPYRIDINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EDITORIAL; HEALTH PROGRAM; HUMAN; MEDICAL INFORMATION; MEDICAL INSTRUMENTATION; MEDICAL LITERATURE; META ANALYSIS; MORTALITY; POST HOC ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

BLOOD VESSEL PROSTHESIS; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SIROLIMUS; STENTS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 34548864075     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.07.026     Document Type: Editorial

References (26)

1. Flather M.D., Farkouh M.E., Pogue J.M., and Yusuf S. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials 18 (1997) 568-579
2. Cleophas T.J., and Zwinderman A.H. Meta-analysis. Circulation 115 (2007) 2870-2875
3. Feinstein A.R. Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 48 (1995) 71-79
4. LeLorier J., Gregoire G., Benhaddad A., Lapierre J., and Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337 (1997) 536-542
5. Schömig A., Dibra A., Windecker S., et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1373-1380
6. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
7. Silber S. A new and rapid scoring system to access the scientific evidence from clinical trials. J Interv Cardiol 19 (2006) 485-492
8. Pinto D.S., Stone G.W., Ellis S.G., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36
9. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
10. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
11. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., and Schomig A. Randomized trial of paclitaxel-and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
12. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
13. Moses J.W., Leon M.B., Popma J.J., et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
14. Stone G.W., Ellis S.G., Cox D.A., et al., Taxus IV Investigators. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
15. Mauri L., Orav E.J., and Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 111 (2005) 3435-3442
16. Pocock S., Stone G.W., Fahy M., et al. Relationship between late loss, diameter stenosis and target lesion revascularization after stent implantation: an examination of surrogate endpoints from a pooled analysis of eight large randomized DES trials. (abstr). J Am Coll Cardiol 47 (2006) 188A
17. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
18. Stone G.W., and SPIRIT III Investigators. Clinical, angiographic, and IVUS results from the pivotal U.S. randomized SPIRIT III Trial of the XIENCE V Everolimus Eluting Coronary Stent System (2007) Paper presented at: ACC 56th Annual Scientific Session; March 24-27; New Orleans, LA.
19. Krucoff M., and COSTAR II Investigators. Multicenter randomized evaluation of a novel paclitaxel eluting stent with bioabsorbable polymer for the treatment of single and multivessel coronary disease: primary results of the CObalt Chromium STent with Antiproliferative for Restenosis II (COSTAR II) study (2007) Paper presented at: Euro PCR 2007 Late Breaking Trial Presentation; March 22-25; Barcelona, Spain.
20. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 49 (2007) 2320-2328
21. Mauri L., Hsieh W., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
22. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
23. Kim Y.H., Park S.W., Lee S.W., et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 (2006) 2148-2153
24. Silber S. Cypher versus Taxus: are there differences?. J Interv Cardiol 18 (2005) 441-446
25. Muni N.I., Califf R.M., Foy J.R., Boam A.B., Zuckerman B.D., and Kuntz R.E. Coronary drug-eluting stent development: issues in trial design. Am Heart J 149 (2005) 415-433
26. Krucoff M.W., Boam A., and Schultz D.G. Drug-eluting stents "deliver heartburn" how do we spell relief going forward?. Circulation 115 (2007) 2990-2994